SCHEMBL7745689

SCHEMBL7745689

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1ccccc1.O=C(Nc1ccc(C(F)(F)F)c(C(F)(F)F)c1)c1ccccc1NCc1ccncc1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.69
FLT1 P17948 7/20 0.69
KIT P10721 2/20 0.69
ABL1 P00519 1/20 0.69
EGFR P00533 1/20 0.69
CSF1R P07333 1/20 0.69
PDGFRB P09619 1/20 0.69
FLT4 P35916 1/20 0.69
RXFP1 Q9HBX9 7/20 0.60
BRAF P15056 1/20 0.54
P2RX1 P51575 1/20 0.51
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
NR1H4 Q96RI1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978394 0.90 KDR (0.74) KDRFLT1KITABL1EGFR
SCHEMBL4981324 0.88 KDR (0.84) KDRFLT1KITABL1EGFR
SCHEMBL4981221 0.84 KDR (0.80) KDRFLT1KITABL1EGFR
SCHEMBL4979990 0.82 KDR (0.71) KDRFLT1KITABL1EGFR
SCHEMBL4981328 0.82 KDR (0.71) KDRFLT1KITABL1EGFR
SCHEMBL4980207 0.82 KDR (0.77) KDRFLT1KITABL1EGFR
SCHEMBL4976103 0.82 KDR (1.00) KDRFLT1KITABL1EGFR
SCHEMBL29356168 0.82 KDR (1.00) KDRFLT1KITABL1EGFR
SCHEMBL4982066 0.81 KDR (0.76) KDRFLT1KITABL1EGFR
SCHEMBL1009579 0.81 KDR (0.70) KDRFLT1KITABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1129075-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS Novartis AG (CH) 2001-09-05 EP disclosed
WO-2000027820-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2000-05-18 WO disclosed